26 recruiting. 26 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Recruiting 26 |
| Phase 3 | 2 | Recruiting 2 |
Follow Neoadjuvant Therapy: new trials by email Literature Review of Neoadjuvant Therapy trials Research Report on Neoadjuvant Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial Retlirafusp alfa, Famitinib malate, Gemcitabine & oxaliplatin - Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 81 | 2026-09-30 | 2026-10-28 |
| Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma Firmonertinib 80mg qd oral for 8 weeks., Firmonertinib 160mg qd oral for 8 weeks., Firmonertinib 80mg qd oral for 16 weeks. - NSCLC, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 60 | 2026-09-03 | 2026-10-27 |
| Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma Camrelizumab, Esophagectomy, Sample - Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 45 | 2026-08-17 | 2026-10-02 |
| Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma Ivonescimab（AK112), Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy, Esophagectomy, Sample - Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 49 | 2026-06-03 | 2026-10-02 |
| Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma Nimotuzumab Injection, Tislelizumab, Albumin-Bound Paclitaxel /nab-Paclitaxel - Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 182 | 2026-04-20 | 2026-07-09 |
| Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy QL1706 combined with Chemotherapy - Breast Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 40 | 2026-04-14 | 2026-09-28 |
| Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma Interferon-γ, Camrelizumab - Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Hefei Cancer Hospital of the Chinese Academy of Sciences | 84 | 2026-03-20 | 2026-08-26 |
| Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer CRT+PD-1 inhibitor+Probio-M9, CRT+PD-1 inhibitor+placebo - Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Seventh Medical Center of PLA General Hospital | 50 | 2026-02-10 | 2026-03-10 |
| Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC fulzerasib - Resectable NSCLC, KRAS G12C Mutation | Phase 2 | Recruiting | Jianxing He | 30 | 2026-01-29 | 2026-03-25 |
| Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma sintilimab combined with bevacizumab biosimilar - Hepatocellular Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Sun Yat-sen University | 37 | 2026-01-14 | 2026-01-16 |
| Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC QL1706 Combined With Lenvatinib - Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 25 | 2025-11-21 | 2026-02-05 |
| Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) Long-course radiotherapy, Oxaliplatin, Capecitabine - Locally Advanced Rectal Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Fudan University | 138 | 2025-08-28 | 2025-09-02 |
| Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05) Iparomlimab and Tuvonralimab, Oxaliplatin, Tegafur - Immunotherapy, Gastric Cancer (GC) | Phase 2 | Recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 40 | 2025-07-23 | 2025-09-10 |
| Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC Pucotenlimab combination with Vorolanib - Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 2 | Recruiting | Sun Yat-sen University | 21 | 2025-07-10 | 2026-02-04 |
| Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC Nab-Paclitaxel, Tislelizumab, Radical nephroureterectomy (RNU) - Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 35 | 2025-07-05 | 2025-08-17 |
| Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer PD-1 inhibitior, Nab-paclitaxel, distal ureterectomy - Ureteral Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 35 | 2025-07-05 | 2025-08-15 |
| A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma Paclitaxel Polymeric Micelles for Injection and Cisplatin combined with Cadonilimab - Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Sun Jing | 30 | 2025-04-20 | 2025-08-08 |
| Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. Radiation Therapy, Chemoradiotherapy, Consolidation Chemotherapy - Rectal Cancer, Total Neoadjuvant Treatment | Phase 2 / Phase 3 | Recruiting | National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos | 400 | 2025-01-06 | 2026-05-11 |
| Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05) pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy - HER2-positive Breast Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 33 | 2024-12-03 | 2025-02-18 |
| Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer short-course radiotherapy, Ivonescimab, capecitabine - Locally Advanced Rectal Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 45 | 2024-10-16 | 2025-01-31 |
Showing 20 of 26. Sign in to see all of them.
Esophageal Squamous Cell Carcinoma (5) · Carcinoma, Renal Cell (2) · Rectal Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Cirrhosis, Familial, with Pulmonary Hypertension (1) · Colorectal Neoplasms (1) · Fatigue (1) · Head and Neck Neoplasms (1) · Low Anterior Resection Syndrome (1) · Postoperative Complications (1) · Radiation Injuries (1) · Squamous Cell Carcinoma of Head and Neck (1)
Neoplasms (17) · Neoplasms by Site (16) · Carcinoma (10) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms, Glandular and Epithelial (10) · Gastrointestinal Diseases (9) · Gastrointestinal Neoplasms (9) · Carcinoma, Squamous Cell (6) · Esophageal Diseases (5) · Esophageal Neoplasms (5) · Head and Neck Neoplasms (5) · Neoplasms, Squamous Cell (5) · Adenocarcinoma (4)
Capecitabine (4) · Oxaliplatin (4) · 130-nm albumin-bound paclitaxel (3) · Carboplatin (3) · Neoadjuvant Therapy (3) · Radiotherapy (3) · camrelizumab (3) · Albumin-Bound Paclitaxel (2) · Celecoxib (2) · Chemoradiotherapy (2) · Drug Therapy (2) · Esophagectomy (2) · tislelizumab (2) · toripalimab (2) · Abiraterone Acetate (1)
Sun Yat-sen University (4) · Fudan University (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Tianjin Medical University Second Hospital (2) · Army Medical Center of PLA (1) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · First Affiliated Hospital of Zhejiang University (1) · Hefei Cancer Hospital of the Chinese Academy of Sciences (1) · Jianxing He (1) · National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos (1) · Peking University Cancer Hospital & Institute (1) · Seventh Medical Center of PLA General Hospital (1) · Shandong Cancer Hospital and Institute (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Shanghai Zhongshan Hospital (1)
China (25) · Lithuania (1)
Jianan Wang (2) · Audrius Dulskas, PhD (1) · Bin Wang (1) · Feng Cheng, MD (1) · Hailong Hu, PhD (1) · Hongzhi Wang (1) · Jingjing Wang (1) · Jun Zhang (1) · Tao Zhang, MD (1) · Yanhong Deng, M.D. (1) · Yongsheng Jia (1) · Zhen Zhang, M.D, PH.D (1) · Zhen Zhang, MD (1)
PMID 34606846, PMID 34688374, PMID 37409565, PMID 40348946, PMID 42320986, PMID 42385761